WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H317879
CAS#: 2022-85-7
Description: Flucytosine, a fluorinated pyrimidine analogue, is a synthetic antimycotic drug. It is structurally related to the cytostatic fluorouracil and to floxuridine. Oral flucytosine is indicated for the treatment of serious infections caused by susceptible strains of Candida or Cryptococcus neoformans. It can also be used for the treatment of chromomycosis (chromoblastomycosis), if susceptible strains cause the infection.
Hodoodo Cat#: H317879
Name: Flucytosine
CAS#: 2022-85-7
Chemical Formula: C4H4FN3O
Exact Mass: 129.03
Molecular Weight: 129.093
Elemental Analysis: C, 37.22; H, 3.12; F, 14.72; N, 32.55; O, 12.39
Synonym: Flucytosine, 5-fluorocytosine, Flucytosin, Ancobon, Ancotil
IUPAC/Chemical Name: 6-amino-5-fluoro-1H-pyrimidin-2-one
InChi Key: XRECTZIEBJDKEO-UHFFFAOYSA-N
InChi Code: InChI=1S/C4H4FN3O/c5-2-1-7-4(9)8-3(2)6/h1H,(H3,6,7,8,9)
SMILES Code: O=C1N=CC(F)=C(N)N1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 129.09 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Yao ZW, Lu X, Shen C, Lin DF. Comparison of flucytosine and fluconazole combined with amphotericin B for the treatment of HIV-associated cryptococcal meningitis: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis. 2014 Aug;33(8):1339-44. doi: 10.1007/s10096-014-2074-2. Epub 2014 Feb 20. Review. PubMed PMID: 24550039.
2: Loyse A, Dromer F, Day J, Lortholary O, Harrison TS. Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal. J Antimicrob Chemother. 2013 Nov;68(11):2435-44. doi: 10.1093/jac/dkt221. Epub 2013 Jun 20. Review. PubMed PMID: 23788479; PubMed Central PMCID: PMC3797641.
3: Patel R. Antifungal agents. Part I. Amphotericin B preparations and flucytosine. Mayo Clin Proc. 1998 Dec;73(12):1205-25. Review. PubMed PMID: 9868423.
4: Marinová I, Szabadosová V, Brandeburová O, Krcméry V Jr. Rhodotorula spp. fungemia in an immunocompromised boy after neurosurgery successfully treated with miconazole and 5-flucytosine: case report and review of the literature. Chemotherapy. 1994 Jul-Aug;40(4):287-9. Review. PubMed PMID: 8082417.
5: Heidemann H. Prevention of amphotericin B nephrotoxicity: the effect of salt loading and flucytosine. Mykosen Suppl. 1988;2:39-44. Review. PubMed PMID: 3078022.
6: Heidemann H. Prevention of amphotericin B nephrotoxicity: the effect of salt loading and flucytosine. Mycoses. 1988;31 Suppl 2:39-44. Review. PubMed PMID: 3067090.
7: Gerson B. Flucytosine (5-fluorocytosine). Clin Lab Med. 1987 Sep;7(3):541-4. Review. PubMed PMID: 3308294.
8: Bennet JE. Flucytosine. Ann Intern Med. 1977 Mar;86(3):319-21. Review. PubMed PMID: 320931.
9: Polak A. [Flucytosine - a classical partner for combination therapy]. Mycoses. 2002;45 Suppl 3:31-3. Review. German. PubMed PMID: 12690968.
10: Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother. 2000 Aug;46(2):171-9. Review. PubMed PMID: 10933638.
11: Viviani MA. Flucytosine--what is its future? J Antimicrob Chemother. 1995 Feb;35(2):241-4. Review. PubMed PMID: 7759388.
12: Francis P, Walsh TJ. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis. 1992 Dec;15(6):1003-18. Review. PubMed PMID: 1457631.
13: Paladino JA, Crass RE. Amphotericin B and flucytosine in the treatment of candidal cystitis. Clin Pharm. 1982 Jul-Aug;1(4):349-52. Review. PubMed PMID: 6764395.